Arcellx: Partial Clinical Hold Lifted By FDA On IMMagine-1 Phase 2 Trial; Q2 Net Loss Narrows
Arcellx, Inc. (ACLX), a clinical-stage biotechnology company, announced that the U.S. Food and Drug Administration has lifted the partial clinical hold placed on its CART-ddBCMA investigational new drug for the treatment of patients with relapsed or refractory multiple myeloma or rrMM.
Source: rttnews.com